Study of DM002 for advanced solid tumors
Part of Cancer, Digestive system, Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new drug called DM002 for people with advanced solid tumors that have not responded to standard treatments. The drug targets two proteins (MUC1 and HER3) found on some cancer cells, and may help shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your cancer is advanced and has spread (stage IV) and is measurable on scans (CT/MRI).
- You have good enough kidney, liver, and blood counts (checked by blood tests).
- You cannot have had other cancer treatment (chemo, radiation, immunotherapy) within the last 4 weeks before starting this study.
- You need to provide an old tumor sample or be willing to have a new biopsy if needed.
- You cannot have untreated brain metastases, serious lung disease, or major heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called DM005 for people with advanced solid tumors (like lung, stomach, colon, liver, pancreas, or head and neck cancer) that have not responded to or can't tolerate standard treatments. The goal is to see if DM005 is safe and how well it works.
This trial tests a new drug, D3L-002, for people with advanced solid tumors that have stopped responding to at least one prior treatment or have no standard options. The goal is to see if it can help shrink or control the cancer.
This trial tests a new drug called DNP002 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if DNP002 is safe and can help shrink tumors or slow their growth.
This trial is testing a new drug called HDM2020 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if the drug is safe and how well it works.
This trial tests a new drug, HDM2012, in people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective, especially for gastric and colorectal cancers.
This trial tests a new drug, HDM2005, in people with advanced solid tumors that have stopped responding to other treatments. It aims to see if the drug is safe and effective for tumors that show a specific marker called ROR1.
Hear when a new Ovarian Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.